Literature DB >> 36266560

Therapeutic Response After Immunosuppressive Drug Prescription in Non-infectious Uveitis: A Survival Analysis.

Alejandro Gómez-Gómez1,2, Alfredo Madrid-Garcia3, Lara Borrego-Sanz4, Paula Álvarez-Hernández5, Pedro Arriola-Villalobos4, Inés Pérez-Sancristobal5, José M Benítez Del Castillo4, Rosalía Mendez-Fernandez4, Esperanza Pato-Cour5, David Díaz-Valle4, Luis Rodriguez-Rodriguez6.   

Abstract

INTRODUCTION: To identify factors affecting the response rate to immunosuppressive drugs (ISDs) in patients with non-infectious uveitis (NIU).
METHODS: This longitudinal retrospective cohort study included patients from the Hospital Clinico San Carlos Uveitis Clinic diagnosed with NIU from 1992 to 2016. Subjects were followed up from ISD prescription until the achievement of good therapeutic response (GTR), ISD treatment change, or up to 12 months. GTR was defined as the complete resolution of the eye inflammatory manifestations with a corticosteroid dose ≤ 10 or ≤ 5 mg per day of prednisone or equivalent (GTR10 and GTR5, respectively) maintained for at least 28 days. Kaplan-Meier curves were estimated for GTR. Demographic, clinical, and treatment-related factors were analyzed using Cox robust regression.
RESULTS: A total of 73 patients (100 episodes of ISD prescription) were analyzed. In 44 and 41 episodes, GTR10 and GTR5 were achieved, respectively. A lower hazard for both GTRs was associated with uveitic macular edema at prescription and with a higher "highest oral corticosteroid dose prescribed in the year before ISD prescription". GTR10 was higher if cyclosporine was prescribed (compared to other ISDs), and if a higher number of ISDs had been previously prescribed. GTR5 hazard was lower for patients with posterior uveitis or if the ISDs were prescribed before 2008, and higher if periocular corticosteroids had been administered before ISD prescription, or if the duration of the posterior segment activity was shorter.
CONCLUSIONS: Factors associated with GTR to ISDs may help to identify patients with NIUs who could benefit from a thorough follow-up.
© 2022. The Author(s).

Entities:  

Keywords:  Immunosuppressive drugs; Response to therapy; Uveitis

Year:  2022        PMID: 36266560     DOI: 10.1007/s40123-022-00587-8

Source DB:  PubMed          Journal:  Ophthalmol Ther


  44 in total

Review 1.  The natural history of uveitis.

Authors:  R B Nussenblatt
Journal:  Int Ophthalmol       Date:  1990-10       Impact factor: 2.031

2.  Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative.

Authors:  Andrew D Dick; James T Rosenbaum; Hassan A Al-Dhibi; Rubens Belfort; Antoine P Brézin; Soon Phaik Chee; Janet L Davis; Athimalaipet V Ramanan; Koh-Hei Sonoda; Ester Carreño; Heloisa Nascimento; Sawsen Salah; Sherveen Salek; Jay Siak; Laura Steeples
Journal:  Ophthalmology       Date:  2018-01-06       Impact factor: 12.079

3.  Patterns of uveitis as a guide in making rheumatologic and immunologic diagnoses.

Authors:  A Bañares; J A Jover; B Fernández-Gutiérrez; J M Benítez del Castillo; J García; E Vargas; C Hernández-García
Journal:  Arthritis Rheum       Date:  1997-02

Review 4.  Immunosuppression for the Uveitides.

Authors:  Douglas A Jabs
Journal:  Ophthalmology       Date:  2017-09-20       Impact factor: 12.079

5.  The current status of biological treatment for uveitis.

Authors:  Carla Gaggiano; Jurgen Sota; Stefano Gentileschi; Valeria Caggiano; Salvatore Grosso; Gian Marco Tosi; Bruno Frediani; Luca Cantarini; Claudia Fabiani
Journal:  Expert Rev Clin Immunol       Date:  2020-08-01       Impact factor: 4.473

Review 6.  The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management.

Authors:  C Stephen Foster; Srishti Kothari; Stephen D Anesi; Albert T Vitale; David Chu; Jamie Lynne Metzinger; Olga Cerón
Journal:  Surv Ophthalmol       Date:  2015-07-09       Impact factor: 6.048

7.  EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases.

Authors:  N Duru; M C van der Goes; J W G Jacobs; T Andrews; M Boers; F Buttgereit; N Caeyers; M Cutolo; S Halliday; J A P Da Silva; J R Kirwan; D Ray; J Rovensky; G Severijns; R Westhovens; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2013-07-19       Impact factor: 19.103

8.  Influence of baseline demographic and clinical characteristics in the visual outcome of intermediate uveitis: a survival analysis.

Authors:  Lydia Abásolo; Ángela Prieto-García; David Díaz-Valle; José Manuel Benítez-Del-Castillo; Esperanza Pato; Julián García-Feijoo; Benjamín Fernández-Gutiérrez; Luis Rodriguez-Rodriguez
Journal:  Br J Ophthalmol       Date:  2016-03-30       Impact factor: 4.638

Review 9.  Review on the worldwide epidemiology of uveitis.

Authors:  Elisabetta Miserocchi; Giovanni Fogliato; Giulio Modorati; Francesco Bandello
Journal:  Eur J Ophthalmol       Date:  2013-05-03       Impact factor: 2.597

10.  Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis.

Authors:  Jennifer E Thorne; Martha Skup; Namita Tundia; Dendy Macaulay; Cindy Revol; Jingdong Chao; Avani Joshi; Andrew D Dick
Journal:  Acta Ophthalmol       Date:  2016-03-02       Impact factor: 3.761

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.